FDA approves Biocon Biologics' Pebrilzo, a pertuzumab product
The agency cleared the biologics license application for Pebrilzo on November 12, 2026, with the label dated November 13, 2026.
Drugs@FDA
3 stories
The agency cleared the biologics license application for Pebrilzo on November 12, 2026, with the label dated November 13, 2026.
Drugs@FDA
Pfizer lifted full-year revenue and EPS guidance on third-quarter results and detailed regulatory approvals for Talzenna, Tukysa and a positive Elrexfio Phase 3 readout.
SEC filing (9)